<?xml version='1.0' encoding='utf-8'?>
<document id="26692192"><sentence text="Development of a Physiologically Based Pharmacokinetic Model for Itraconazole Pharmacokinetics and Drug-Drug Interaction Prediction."><entity charOffset="65-77" id="DDI-PubMed.26692192.s1.e0" text="Itraconazole" /></sentence><sentence text="Physiologically based pharmacokinetic (PBPK) modeling for itraconazole has been challenging due to highly variable in vitro d ata used for 'bottom-up' model building"><entity charOffset="58-70" id="DDI-PubMed.26692192.s2.e0" text="itraconazole" /></sentence><sentence text=" Under-prediction of pharmacokinetics and drug-drug interactions (DDIs) following multiple doses of itraconazole has limited the use of PBPK model simulation to aid an itraconazole clinical DDI study design"><entity charOffset="100-112" id="DDI-PubMed.26692192.s3.e0" text="itraconazole" /><entity charOffset="168-180" id="DDI-PubMed.26692192.s3.e1" text="itraconazole" /><pair ddi="false" e1="DDI-PubMed.26692192.s3.e0" e2="DDI-PubMed.26692192.s3.e0" /><pair ddi="false" e1="DDI-PubMed.26692192.s3.e0" e2="DDI-PubMed.26692192.s3.e1" /></sentence><sentence text=" The aim of this work is to develop an itraconazole PBPK model predominantly using a 'top-down' approach to enable a more accurate pharmacokinetic and DDI prediction"><entity charOffset="39-51" id="DDI-PubMed.26692192.s4.e0" text="itraconazole" /></sentence><sentence text="" /><sentence text="An itraconazole PBPK model describing itraconazole and hydroxyl-itraconazole (OH-ITZ) was constructed in Simcyp(Â®)"><entity charOffset="3-15" id="DDI-PubMed.26692192.s6.e0" text="itraconazole" /><entity charOffset="38-50" id="DDI-PubMed.26692192.s6.e1" text="itraconazole" /><entity charOffset="55-76" id="DDI-PubMed.26692192.s6.e2" text="hydroxyl-itraconazole" /><entity charOffset="78-84" id="DDI-PubMed.26692192.s6.e3" text="OH-ITZ" /><pair ddi="false" e1="DDI-PubMed.26692192.s6.e0" e2="DDI-PubMed.26692192.s6.e0" /><pair ddi="false" e1="DDI-PubMed.26692192.s6.e0" e2="DDI-PubMed.26692192.s6.e1" /><pair ddi="false" e1="DDI-PubMed.26692192.s6.e0" e2="DDI-PubMed.26692192.s6.e2" /><pair ddi="false" e1="DDI-PubMed.26692192.s6.e0" e2="DDI-PubMed.26692192.s6.e3" /><pair ddi="false" e1="DDI-PubMed.26692192.s6.e1" e2="DDI-PubMed.26692192.s6.e1" /><pair ddi="false" e1="DDI-PubMed.26692192.s6.e1" e2="DDI-PubMed.26692192.s6.e2" /><pair ddi="false" e1="DDI-PubMed.26692192.s6.e1" e2="DDI-PubMed.26692192.s6.e3" /><pair ddi="false" e1="DDI-PubMed.26692192.s6.e2" e2="DDI-PubMed.26692192.s6.e2" /><pair ddi="false" e1="DDI-PubMed.26692192.s6.e2" e2="DDI-PubMed.26692192.s6.e3" /></sentence><sentence text=" The key parameters that govern the pharmacokinetic profile, including non-linear clearance (i" /><sentence text="e" /><sentence text=", maximum rate of reaction [V max] and the Michaelis-Menten constant [K m]) and volume of distribution for both itraconazole and OH-ITZ, were redefined by leveraging existing in vivo data"><entity charOffset="112-124" id="DDI-PubMed.26692192.s9.e0" text="itraconazole" /><entity charOffset="129-135" id="DDI-PubMed.26692192.s9.e1" text="OH-ITZ" /><pair ddi="false" e1="DDI-PubMed.26692192.s9.e0" e2="DDI-PubMed.26692192.s9.e0" /><pair ddi="false" e1="DDI-PubMed.26692192.s9.e0" e2="DDI-PubMed.26692192.s9.e1" /></sentence><sentence text=" Model verification was performed by comparing the simulated itraconazole and OH-ITZ pharmacokinetic profiles with the observed clinical data"><entity charOffset="61-73" id="DDI-PubMed.26692192.s10.e0" text="itraconazole" /></sentence><sentence text=" Finally, the model was used to simulate clinical DDIs between itraconazole and midazolam"><entity charOffset="63-75" id="DDI-PubMed.26692192.s11.e0" text="itraconazole" /><entity charOffset="80-89" id="DDI-PubMed.26692192.s11.e1" text="midazolam" /><pair ddi="false" e1="DDI-PubMed.26692192.s11.e0" e2="DDI-PubMed.26692192.s11.e0" /><pair ddi="false" e1="DDI-PubMed.26692192.s11.e0" e2="DDI-PubMed.26692192.s11.e1" /></sentence><sentence text="" /><sentence text="The developed PBPK model well-described the pharmacokinetics of itraconazole and OH-ITZ, and particularly captured their accumulation after repeated doses of itraconazole"><entity charOffset="64-76" id="DDI-PubMed.26692192.s13.e0" text="itraconazole" /><entity charOffset="81-87" id="DDI-PubMed.26692192.s13.e1" text="OH-ITZ" /><entity charOffset="158-170" id="DDI-PubMed.26692192.s13.e2" text="itraconazole" /><pair ddi="false" e1="DDI-PubMed.26692192.s13.e0" e2="DDI-PubMed.26692192.s13.e0" /><pair ddi="false" e1="DDI-PubMed.26692192.s13.e0" e2="DDI-PubMed.26692192.s13.e1" /><pair ddi="false" e1="DDI-PubMed.26692192.s13.e0" e2="DDI-PubMed.26692192.s13.e2" /><pair ddi="false" e1="DDI-PubMed.26692192.s13.e1" e2="DDI-PubMed.26692192.s13.e1" /><pair ddi="false" e1="DDI-PubMed.26692192.s13.e1" e2="DDI-PubMed.26692192.s13.e2" /></sentence><sentence text=" This was verified with the observed data from 29 clinical studies where itraconazole solution or capsule was given as a single or multiple dose"><entity charOffset="73-85" id="DDI-PubMed.26692192.s14.e0" text="itraconazole" /></sentence><sentence text=" The predicted DDI between itraconazole and midazolam was within 1"><entity charOffset="27-39" id="DDI-PubMed.26692192.s15.e0" text="itraconazole" /><entity charOffset="44-53" id="DDI-PubMed.26692192.s15.e1" text="midazolam" /><pair ddi="false" e1="DDI-PubMed.26692192.s15.e0" e2="DDI-PubMed.26692192.s15.e0" /><pair ddi="false" e1="DDI-PubMed.26692192.s15.e0" e2="DDI-PubMed.26692192.s15.e1" /></sentence><sentence text="25-fold of the observed data for seven of ten studies and within 1" /><sentence text="5-fold for nine of ten studies" /><sentence text="" /><sentence text="The improvement of the itraconazole PBPK model increased our confidence in using PBPK model simulations to optimize clinical itraconazole DDI study design"><entity charOffset="23-35" id="DDI-PubMed.26692192.s19.e0" text="itraconazole" /></sentence><sentence text="" /></document>